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11 Introduction
Young adults suﬀering from chronic kidney disease (CKD) have an excessively elevated
risk of developing atherosclerosis and cardiovasclular disease (CVD). High density lipopro-
teins (HDL) have antiatherogenic potential, mainly through reverse cholesterol transport
(RCT) from peripheral tissues to the liver. In CKD the composition of the HDL particles
is abnormal, which might reduce their capacity as an acceptor for cellular cholesterol
and thus impair macrophage cholesterol eux and RCT. It is speculated that the al-
terations in HDL composition and function present in CKD patients may contribute to
CVD development as they may counteract the antiatherogenic properties of HDL. Still,
the potential inﬂuence of CKD on lipoprotein metabolism and RCT is incompletely un-
derstood (Holzer et al., 2011b).
The aim of this study was to determine
• the cholesterol acceptor capacity of serum and HDL, obtained from adult and
pediatric CKD patients, dialysis patients and from healthy, matched controls, and
• the cholesterol eux capacity of human monocyte-derived macrophages (HMDM)
isolated from the study participants and from healthy, matched controls.
1.1 Atherosclerosis
1.1.1 Epidemiology of atherosclerosis
Cardiovascular disease is the major cause of deaths in industrialized societies (Wang and
Tall, 2003; Basnakian et al., 2010) and responsible for 30% of all deaths worldwide in
2005 (WHO, 2008) and 50% of all deaths in Western societies (Lusis, 2000).
Atherosclerosis, the underlying cause of CVD, is a chronic, progressive disease that is
characterized by lipid accumulations and chronic inﬂammation in the intima of the arterial
wall (Lundberg and Hansson, 2010; Andersson et al., 2010). It is associated with of a
combination of exogenous and endogenous risk factors (Chade et al., 2005; Cooney et al.,
2009) which include hypertension, diabetes, dyslipidemia (e.g. high (LDL), low (HDL)),
high fat diet, smoking, increased oxidative stress and genetic predisposition (Glass and
Witztum, 2001; Chade et al., 2005; Menon et al., 2005). Progressing from early lesions
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of the arterial wall to ﬁbrous plaque formation (Navab et al., 1996; Ross, 1999), it
can lead to acute clinical events, like myocardial infarction or stroke eventually (Lusis,
2000; McGill et al., 2000). Prevention of atherosclerosis should begin in adolescence by
attempting to control the known risk factors (McGill et al., 2000).
1.1.2 Pathogenesis of atherosclerosis
Development of fatty streaks
The development of atherosclerosis starts in childhood by formation of so called fatty
streaks, which represent the earliest type of atherosclerotic lesion (McGill et al., 2000;
Napoli et al., 1997). One of the primary events of atherogenesis is the accumulation
of LDL in the subendothelial matrix (Fig. 1.1 a). In areas where the endothelium is
subject to constant shear stress it becomes dysfunctional. Furthermore, ROS can be held
resposible for initiating key events in atherosclerosis, namely inactivation of nitric oxide
(NO) and oxidation of LDL, which leads to a cycle in which oxidized LDL (oxLDL) in turn
stimulates the production of reactive oxygen species (ROS) (Chade et al., 2002; Amann
et al., 2002; Chade et al., 2003). LDL passes through endothelial cell (EC) junctions by
passive diﬀusion and is then oxidized, which is initiated by exposure to 'oxidative waste
of vascular cells' (Lusis et al., 2004). The accumulation of modiﬁed LDL stimulates ECs
to produce adhesion molecules, like vascular cell adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule 1 (ICAM-1), which are indispensable for the adhesion of
monocytes to activated vascular ECs (Apostolov et al., 2007b, a), as well as growth
factors, like macrophage colony-stimulating factor (M -CSF) (Lusis, 2000). Recruitment
of monocytes and lymphocytes to the intima of the artery wall is a main characteristic
of atherosclerotic disease (Apostolov et al., 2007b, a).
P- and E- selectins mediate the ﬁrst step of the binding process, the leukocyte 'rolling'
along the endothelial surface. Adhesion molecules and chemotactic factors mediate the
entry of certain leukocytes, in particular monocytes, in the arterial wall (Lusis, 2000).
1.1 Atherosclerosis 3
Fig. 1.1: Atherosclerosis progression (Rader and Daugherty, 2008)
Monocytes adhere to endothelial cells and migrate into the vessel wall where they diﬀer-
entiate to macrophages (Lusis, 2000; Apostolov et al., 2007b). Macrophages play a key
role in atherogenesis, as they take up and store cholesterol from modiﬁed LDL via scav-
enger receptors, like scavenger receptor class A (SR-A) and cluster of diﬀerentiation 36
(CD36) (Tontonoz et al., 1998; Lusis, 2000). Peroxisome proliferator activated receptor-
g (PPAR-g) and cytokines (like tumor necrosis factor-a (TNF-a) and interferon-g (IFN-
g)) regulate the expression of these scavenger receptors. In contrast to the LDL receptor
(LDLR), SR-A and CD36 are not down-regulated when the cholesterol content of the
macrophages increases, which causes unregulated cholesterol uptake and leads to foam
cell formation (Llaverias et al., 2005). The resulting early lesions, so called fatty streaks,
consist primarily of lipid-laden macrophages, and are not clinically signiﬁcant, but in part
progress to the more advanced ﬁbrous lesions (Lusis, 2000).
Development of advanced lesions
monocyte-derived macrophages and T-lymphocytes present in the atherosclerotic plaque
can produce several cytokines (like interleukin-6 (IL-6) or IL-18), chemokines (like mono-
cyte chemoattractant protein-1 (MCP-1)), growth factors, enzymes (like myeloperoxi-
dase (MPO)), and disintegrins which activate ECs and smooth muscle cells (SMCs)
(Fig. 1.1 b)(Koenig and Khuseyinova, 2007). SMCs are caused to migrate to the intima
from the medial layer and accumulate in fatty streaks where they secrete collagen which
leads to the formation of a ﬁbrous cap (Fig. 1.1 c). The process continues by further
migration of mononuclear cells from the blood (Lusis, 2000; Lusis et al., 2004). As the
atherosclerotic plaque increases in size, it starts to narrow the vessel lumen. Ulceration
of the plaque results in thrombosis, intramural bleeding, calciﬁcation and complications
like aneurysma, restriction or occlusion of the vessel-lumen and embolism (Fig. 1.1 c,
d) (Lippi et al., 2011).
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1.2 Chronic kidney disease
1.2.1 Epidemiology of chronic kidney disease
Chronic kidney disease, like atherosclerosis, is a worldwide health problem (Sarnak et al.,
2003; Chade et al., 2005; Foundation, 2002) that aﬀects approximately 11% of the adult
population (Levey et al., 2003). In the past decade, incidence and prevalence of CKD
have been rising and are expected to increase further (The National Kidney Foundation,
2002; Levey et al., 2003), while the population with end-stage renal disease (ESRD) has
more than doubled (Chade et al., 2005).
Cardiovascular disease (CVD) contributes to the development and progression of renal
injury through pathogenic mechanisms such as endothelial dysfunction, and inﬂammation
(Chade et al., 2005).
CVD risk factors, such as older age, diabetes mellitus, systolic hypertension, dyslipi-
demia, hyperhomocysteinemia, oxidative stress and elevated inﬂammatory markers are
also prevalent in CKD (The National Kidney Foundation, 2002). In the US >65% of all
cases of ESRD are caused by diabetes and hypertension. For prevention and treatment
of CKD it is crucial to recognize and treat the risk factors at an early stage of the disease
(Chade et al., 2005).
The National Kidney Foundation deﬁned CKD as:
1. kidney damage for >3 months, as deﬁned by structural or functinonal abnormalities
of the kidney, with or without decreased glomerular ﬁltration rate (GFR),
manifest by either:
• pathological abnormalities, or
• markers of kidney damage, including abnormalities in the composition of the blood
or urine, or abnormalities in imaging tests.
2. GFR<60 mL/min/1.73 m² for >3 months, with or without kidney damage.
Based on measured or estimated (from serum creatinine) glomerular ﬁltration rate (GFR;
reference values: 90-120 ml/min/1.73m²; see table 1) the 'Stages of chronic kidney
disease' were established in the K/DOQI CKD Guidelines (Kidney Disease Outcomes
Quality Initiative; see table 1) (The National Kidney Foundation, 2002).
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Tab. 2: Stages of Chronic Kidney Disease
Stage Description GFR (ml/min/1.73m²)
1 Kidney damage with normal or ^ GFR ≥90
2 Kidney damage with mild _ GFR 60-89
3 Moderate _ GFR 30-59
4 Severe _ GFR 15-29
5 Kidney failure <15 or dialysis
(The National Kidney Foundation, 2002)
Albuminuria, that is, presence of abnormal quantities of albumin in the urine, may precede
functional impairment, and may be accompanied by a lowered GFR and therefore is a
possibility to identify renal disease and an independent marker of CV risk (Schiﬀrin et al.,
2007).
1.2.2 Atherogenic alterations of lipoprotein metabolism in chronic kidney
disease
CKD is known to cause oxidative stress, inﬂammation, lipoprotein oxidation, impaired
lipoprotein metabolism and to enhance atherosclerosis (Moradi et al., 2009b; Sarnak
et al., 2003). An inﬂammatory response may be triggered by changes in plasma com-
ponents, as well as by alteration of endothelial structure and function (Schiﬀrin et al.,
2007). The proceeding impairment of renal function in CKD, leading to dyslipidemia
and/or accumulation of uremic toxins, may play a role in the progression of endothelial
dysfunction and atherogenesis (Schiﬀrin et al., 2007; Kwan et al., 2007). The higher
amount of reactive oxygen species (ROS) present in CKD increases the oxidation of
lipids, carbohydrates and protein, and rises as the disease progresses, which again can
favor atherogenesis (Chade et al., 2002; Amann et al., 2002; Chade et al., 2003).
In CKD patients, total and LDL-cholesterol levels are often normal, however, LDL are
more sensitive to oxidation (Maggi et al., 1994) and subject to signiﬁcantly increased
carbamylation (Apostolov et al., 2005). The resulting proatherogenic eﬀect is comprised
of EC activation by modiﬁed LDL, and thus enhanced ICAM-1 and VCAM-1 expression,
followed by monocyte adhesion (Apostolov et al., 2007a).
Due to accumulation of intermediate density lipoproteins (IDL), which contain very low
density lipoprotein (VLDL) and chylomicron remnants, plasma triglyceride levels are
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increased. Moreover, HDL maturation is impaired in CRF. As a result, plasma HDL-
levels are diminished and HDL composition is altered (Schiﬀrin et al., 2007; Kwan et al.,
2007). Also, apolipoprotein-AI (apoA-I) synthesis is decreased, which, in addition to
the low plasma-HDL, leads to a diminished potential of HDL to act as an antioxidant
and protector of the endothelium (Chade et al., 2005; Kwan et al., 2007). Therefore,
endothelial function is impaired, which promotes atherosclerosis and enhances the CVD
risk (Schiﬀrin et al., 2007; Kwan et al., 2007).
In 2009 Moradi et al. showed that besides diminished plasma HDL levels, also HDL
quality was impaired due to enhanced oxidation in hemodialysis patients, which resulted
in diminished atheroprotective capacity (Moradi et al., 2009a). Moreover, Weichhart
et al. (2012) demonstrated that the composition of HDL is altered in uremia and that
therefore its anti-atherogenic function is impaired. Hence, HDL quality might be critical
for atherosclerosis progression during CRF (Weichhart et al., 2012).
Recently, Moradi et al. showed that artiﬁcially implemented CRF by 5/6 nephrectomy
in a murine model resulted in aggravated aortic lipid accumulation through enhanced
lipid inﬂux. It was the result of an upregulation of scavenger receptor A1 (SR-A1)
and lectin-like oxidized LDL receptor 1 (LOX-1), which mediate cholesterol inﬂux, as
well as lecithin:cholesterin acyltransferase (LCAT) - which esteriﬁes the euxed choles-
terol - deﬁciency. In this model, the lipid accumulation occurred despite compensatory
upregulation of liver X receptor (LXR), ATP binding cassette (ABC) transporter A1
(ABCA1) and ABCG1, which mediate cholesterol eux (described in detail in section
1.3.4) (Moradi et al., 2009b).
There are studies that point out an inverse relationship between lipid proﬁle and mor-
tality in dialysis, in which lower levels of total cholesterol are associated with increased
mortality (Liu et al., 2004; Iseki et al., 2002). In 2002 Iseki et al. found the highest
10-year mortality rate in subjects with less than 140 mg/dl serum cholesterol at base-
line, and the lowest in subjects with a baseline level between 200 and 219 mg/dl (Iseki
et al., 2002). In 2007 Kilpatrick et al. published a study for which a large national
database of maintenance hemodialysis patients (82,958 subjects) in the United States
had been researched, and reported a phenomenon referred to as 'reverse epidemiology',
which describes an association between total hypercholesterolemia (>200 mg/dl), LDL
hypercholesterolemia as well as hypertriglyeridemia and better survival of hemodialysis
patients (Kilpatrick et al., 2007). However, this is discussed controversially as, among
others, Levin et al. (2007) stated that metabolic outcomes in hemodialysis patients, like
changes in cholesterol level, need to be interpreted diﬀerently in a hemodialysis cohort
than in the general population (Levin et al., 2007).
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1.2.3 The association of chronic kidney disease and atherosclerosis
Oxidative stress, inﬂammation, hypertension and dyslipidemia are regarded to be paramount
among the risk factors that contribute to the development of atherosclerosis and CVD
in CKD (Moradi et al., 2009b). CKD appears to be a risk factor for CVD and patients
suﬀering from CKD are more likely to die from CVD than to develop kidney failure
(Sarnak et al., 2003; Tonelli et al., 2006; Schiﬀrin et al., 2007).
The prevalence of CVD in ESRD patients is remarkably increased, compared to healty
controls (Chade et al., 2005; Sarnak et al., 2003) and about 50% of ESRD patients die
from a cardiovascular event (Schiﬀrin et al., 2007), therefore CVD is the leading cause
of death in patients with ESRD on chronic dialysis (Krediet and Balafa, 2010; Ponda
and Barash, 2008), which is even more distinct in the age group from 25 to 30 years
(Schiﬀrin et al., 2007).
In children and young adults suﬀering from ESRD, there is a high prevalence of coronary
and carotid atherosclerosis and the CVD mortality is increased up to 700-fold as the
development of atherosclerosis starts early in these patients (Oh et al., 2002; Schiﬀrin
et al., 2007). The younger the person studied, the higher the relative risk of CVD in
comparison to the general population (see table 2) (Schiﬀrin et al., 2007).
Tab. 3: CV risk according to stages of CKD
CV risk according to stages of CKD
stage CV risk (odds ratio, univariate)
1 Depending on degree of proteinurea
2 1.5
3 2-4
4 4-10
5 10-50
ESRD 20-1000
The increase in risk in comparison with people free of CKD depends
on the age of the population studied: The younger the person, the
higher the relative risk. Microalbuminurea increases the CV risk 2- to
4-fold.
(modiﬁed after Schiﬀrin et al., 2007)
Atherosclerosis on top of pre-existing renal injury may, as mentioned before, aggravate
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CKD progression via similar pathophysiological pathways (Chade et al., 2005). Glomeru-
lar cells and cells of the vessel wall share some of their characteristics (Ross, 1999;
Abrass, 2004), so atherosclerosis and glomerulosclerosis can be seen as comparable pro-
cesses (Chade et al., 2005). In both, atherogenic lipoproteins can induce cell injury and
trigger growth factor-secretion leading to vascular hypercellularity and proliferation of
extracellular matrix (Ross, 1999). One of the primary events that lead to atherosclerosis
is the deterioration of endothelial function, which is present in renal disease and has been
proposed as the major pathophysiological mechanism involved in the association between
reduced GFR and the increased risk of CV events. The acceleration of atherosclerosis
may be due to a combination of endothelial dysfunction, low-grade inﬂammation, dys-
lipidemia and renal disease, and, furthermore, together with hypertension explain the
elevated prevalence of CV events in CKD (Schiﬀrin et al., 2007).
In 2002, Shoji et al. reported that CKD as well as alterations secondary to CKD, but
not hemodialysis (HD) or HD duration, are responsible for atherosclerosis development
by measuring the intima media thickness of carotid arteries (CA-IMT) with the use of
high-resolution ultrasonography. Other studies however, did ﬁnd a signiﬁcant correlation
between HD duration and CA-IMT (Burdick et al., 1994; Shoji et al., 2002).
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1.3 Lipoproteins
1.3.1 Lipoprotein composition
For transportation in the blood, lipids have to bind to proteins and form the so called
lipoproteins. Lipoproteins consist of a hydrophobic core containing triglycerides and
cholesteryl-esters (CE), which is surrounded by an amphipathic monolayer of phospho-
lipids and free cholesterol (FC) and apolipoproteins (for HDL composition see ﬁg. 1.2)
(Lusis et al., 2004).
Fig. 1.2: HDL composition
Lipoproteins are classiﬁed according to their speciﬁc densities and molecular sizes and
possess diﬀerent physiological functions, lipid composition and apolipoprotein content.
The main lipoprotein classes are: high density lipoprotein (HDL), intermediate density
lipoprotein (IDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL)
and chylomicrons (Krieger, 1999; Kwan et al., 2007). They are usually seperated by
sequential ultracentrifugation or electrophoresis.
1.3.2 Lipoprotein metabolism
There are two main pathways of lipoprotein metabolism - the endogenous pathway, in
which lipoproteins originate in the liver and the exogenous pathway, in which lipoproteins
mainly contain dietary fat (Kwan et al., 2007; see ﬁg. 1.3).
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Fig. 1.3: Lipoprotein metabolism (Kwan 2007)
After absorption dietary lipids (triglycerides, cholesterol) are packaged in chylomicrons.
Lipoprotein lipase (LPL) lipolyzes the chylomicrons and delivers the free fatty acids
(FFA) to the tissues. The remaining chylomicron remnants are taken up by the liver via
the LDL receptor (LDLR) and LDL receptor-related protein (LRP) mediation. In the
liver, triglycerides and cholesterol are actively synthesized and packaged before they are
secreted in VLDL along with lipids originally derived from the intestine. After lipolysis by
LPL, the VLDL particles convert to IDL, half of which are removed from the circulation
by hepatic receptors. The remaining half undergoes further lipolysis resulting in the
formation of LDL. Several enzymes, such as cholesteryl ester transfer protein (CETP),
function in the transfer of lipids between the diﬀerent lipoproteins (Lusis et al., 2004).
The removal of LDL is mediated by the LDLR, in the liver as well as in peripheral tissues
(Lusis et al., 2004).
Chylomicron and VLDL surface remnants, together with precursors secreted by liver and
intestine, form HDL particles (see ﬁg. 1.4). HDL is capable of faciliating the removal
of cellular cholesterol. After esteriﬁcation of the cholesterol by lecithin:cholesterin acyl-
transferase (LCAT), it is transported to the liver via HDL and taken up via scavenger
receptor class B type 1 (SR-B1), for processing and excretion (Lusis et al., 2004).
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1.3.3 HDL in atherosclerosis and chronic kidney disease
High-density lipoprotein (HDL), one of the major carriers of cholesterol in the blood (Po-
drez, 2010), is a strong atheroprotective factor due to its anti-inﬂammatory, antioxidant,
antiapoptotic, antithrombotic and NO-promoting eﬀects and by enhancing endothelial
function (Movva and Rader, 2008). Furthermore, it plays a pivotal role in reverse choles-
terol transport (RCT - described later), which constitutes its strongest antiatherogenic
property (Lusis, 2000; Cutri et al., 2006; Vergeer et al., 2010; Wang and Tall, 2003).
It has been shown (in vitro) that HDL inhibits the expression of endothelial adhesion
molecules, LDL-induced monocyte transmigration (Vergeer et al., 2010) and lipoprotein
oxidation, which contributes to its antiatherogenic eﬀect (Lusis, 2000).
Fig. 1.4: HDL metabolism (Lewis and Rader, 2005)
Low levels of HDL-cholesterol (<40 mg/dl) are an independent risk factor for CVD
(Cho, 2009) and a rise in plasma HDL reduces the relative risk of coronary heart disease
signiﬁcantly (Wilson et al., 1998). However, not only quantity, but also quality of HDL
is critical for cellular cholesterol eux and prevention of cardiovascular events (Chirinos
et al., 2005; Cho, 2009).
Approximately 70% of the total HDL protein content is constituted by apoA-I, which is
synthesized by liver and intestine - other apolipoproteins associated with HDL are apoA-
II (15-20%), A-IV, C-I, C-II, C-III and E (Oram, 2003; Movva and Rader, 2008; Podrez,
2010). The main properties of HDL, lipid binding and cellular cholesterol eux as well as
lecithin:cholesterol acyltransferase (LCAT) activation, are primarily due to apoA-I (Cho,
2009).
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In CKD, the composition of HDL is altered and its anti-inﬂammatory properties are
impaired (Kwan et al., 2007). Initial results in hemodialysis patients including diabet-
ics suggest that the ability of HDL to promote cholesterol eux may also be reduced
(Marsche et al., 2008).The HDL plasma level is diminished in CKD as shown by Gonen
et al. (1985).
1.3.4 Reverse cholesterol transport
Glomset (1968) was the ﬁrst to propose a mechanism now referred to as reverse choles-
terol transport, which describes the mobilization of excess cholesterol from peripheral
tissues and its transport to the liver for disposal (see ﬁg. 1.5) (Lusis, 2000; Cutri et al.,
2006; Vergeer et al., 2010; Wang and Tall, 2003; Pagler et al., 2007; Glomset, 1968). To
prevent foam cell formation and atherosclerosis progression, adequate cholesterol eux
from macrophages is crucial.
Fig. 1.5: Reverse cholesterol transport (Rader et al., 2009)
Cholesterol from modiﬁed LDL is taken up by macrophages mainly via SR-A1/2 and
CD36. The expression of these scavenger receptors is increased in blood monocytes of
CKD patients (Chmielewski et al., 2005).
The initial step of RCT, cellular cholesterol eux to lipid-poor apoA-I, the main apolipopro-
tein of HDL, and mature HDL (Vergeer et al., 2010; Kwan et al., 2007), is mediated
mainly by ABCA1 and ABCG1 (Klucken et al., 2000; Wang et al., 2004; Pagler et al.,
2007) and SR-B1 (Pagler et al., 2006; Ji et al., 1997; Chinetti et al., 2000). The
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cholesterol taken up by HDL is esteriﬁed by LCAT, which is activated by apoA-I, and
transported to the core of the HDL particle, thereby creating the gradient required to
maintain the cholesterol eux from cells to HDL (Cutri et al., 2006; Kwan et al., 2007).
HDL delivers the cholesterol to the liver where it is taken up via SR-B1, a scavenger
receptor with a high aﬃnity for lipid-rich HDL (Cutri et al., 2006; Liadaki et al., 2000).
Cholesterol can also be transferred to VLDL and LDL (apo-B containing lipoproteins),
which is mediated by cholesteryl ester transfer protein (CETP) and followed by either
uptake by the liver via LDLR or delivery to peripheral tissues (Cutri et al., 2006). The
rate of RCT is not always associated with plasma levels of HDL and apoA-I (Movva and
Rader, 2008).
ApoE-/−mice develop severe atherosclerotic lesions spontanously and therefore are used
extensively in atherosclerosis research. Using a murine model, Singaraja et al. (2002)
showed that increased ABCA1 activity leads to a decreased tendency to develop atheroscle-
rotic lesions, as well as increased cholesterol eux from macrophages (Singaraja et al.,
2002).
Increasing cholesterol eux from macrophages has been discussed as a possible treat-
ment for atherosclerosis (Joseph et al., 2002). The eﬀect of CKD/ESRD on cellular
cholesterol eux and the ability of uremic HDL to act as an acceptor for cellular choles-
terol have not yet been studied suﬃciently.
Membrane transporters and receptors relevant for reverse cholesterol trans-
port
ATP binding cassette transporters A1 and G1
ABCA1 and ABCG1 are part of the ABC superfamily, a family of receptors that
typically consist of four transmembrane domains and uses energy gained from ATP
hydrolysis to transport speciﬁc substrates through a membrane against a concentration
gradient (Higgins, 1992). The ABCA1, ABCG1 and apolipoprotein-mediated cholesterol
eux from macrophages plays an important role in protection against atherosclerosis and
ABCA1 expression is up-regulated in cholesterol engorged macrophages of atherosclerotic
lesions (Lusis et al., 2004; Kielar et al., 2001; Lawn et al., 2001).
ABCA1 has a pivotal role in cholesterol homeostasis and HDL metabolism as it mediates
the cholesterol eux to lipid poor forms of apoA-I, probably by direct binding of apoA-I
to ABCA1 and direct transport of cholesterol and phospholipids as substrates (Oram,
2003; Wang and Tall, 2003; Wang et al., 2004).
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ABCG1 stimulates cholesterol eux to mature HDL and therefore take part in the
regulation of lipid eux. ABCG1 expression in HMDM is enhanced in response to
acLDL loading (Nakamura et al., 2004; Klucken et al., 2000; Wang et al., 2004).
Activation of liver X receptor/retinoic acid receptor (LXR/RXR) results in an increase
of ABCA1/ABCG1 expression (Oram, 2003; Wang and Tall, 2003; Wang et al., 2004)
and thus enhances cholesterol eux to apoA-I (Wang et al., 2004). It furthermore
promotes other antiatherogenic mechanisms like bile acid synthesis and inhibition of
intestinal cholesterol absorption. Synthetic LXR ligands, however, in a murine model also
promoted lipogenesis and hypertriglyceridemia which in turn promotes atherosclerosis
(Joseph et al., 2002).
The signiﬁcance of ABCA1/ABCG1 for cellular cholesterol eux probably depends on
both: their relative cellular expression as well as the concentration of apolipoproteins
and HDL (Nakamura et al., 2004) [for review see (Zannis et al., 2006)]. Incubation of
human coronary artery endothelial cells (HCAECs) with uremic plasma led to decreased
expression of these genes (Cardinal et al., 2007).
Scavenger receptor class B type 1
SR-B1 is a membrane glycoprotein of 82 kDa with one large extracellular domain and
two transmembrane domains (Zannis et al., 2006) and acts antiatherogenically in two
ways: it promotes cholesteryl ester (CE) uptake in the liver as well as cellular cholesterol
eux in peripheral tissues (Pagler et al., 2007).
HDL delivers CE to the liver, where SR-B1 mediates CE uptake by hepatocytes without
degradation of the HDL particle (Krieger, 1999). SR-B1 is also present in macrophages
of atherosclerotic lesions (Chinetti et al., 2000; Hirano et al., 1999), where it mediates
cholesterol eux from macrophages to mature HDL (Ji et al., 1997) and therefore con-
tributes to protection against atherosclerosis (Zhang et al., 2003). According to Zhang
et al. (2003), SR-B1 protects ApoE-/−mice from developing atherosclerotic lesions with-
out enhancing macrophage cholesterol eux to HDL or apoA-I or altering plasma lipid
levels or HDL subpopulations. They suggest that the antiatherogenic properties of SR-
B1 might not be related to its ability to eux cellular cholesterol from macrophages
(Zhang et al., 2003).
SR-B1 deﬁciency in mice is associated with an increased risk to develop atherosclerosis
as it aﬀects the lipid and apoprotein composition of HDL (Zannis et al., 2006) [for re-
views on SR-B1 see (Krieger, 1999; Zannis et al., 2006)].
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Duong et al. (2006) demonstrated that a large amount of cholesterol eux from human
WI38VA13 ﬁbroblasts and mouse peritoneal macrophages to the plasma is mediated by
a pathway independent from either ABCA1 and SR-B1 respectively. They showed, that
even after inhibiting both, ABCA1 as well as SR-B1, still a remarkable amout of unin-
hibitable eux occured and suggest this to be due to aqueous diﬀusion to phospholipid
containing acceptors present in plasna and dependend on their concentration (Duong
et al., 2006).
1.3.5 Modiﬁed lipropoteins
Modiﬁed LDL, namely carbamylated LDL (cLDL) and oxidized LDL (oxLDL), which are
remarkably elevated in CKD patients (Apostolov et al., 2005), can induce endothelial
dysfunction and injury (Chade et al., 2005), and show cytotoxicity against ECs, therefore
acting proatherogenic (Ok et al., 2005). It is commonly accepted that the atherosclerotic
process can be initiated by EC-injury due to modiﬁed LDL (Basnakian et al., 2010), as
the expression of adhesion molecules for monocyte binding (e.g. ICAM-1) in ECs is
increased under their inﬂuence (Kamanna et al., 1999).
Lipoprotein oxidation
Oxidatively modiﬁed LDL (oxLDL) is commonly divided in two groups: minimally
modiﬁed LDL (mmLDL) and extensively oxidized LDL (oxLDL). While mmLDL, which
is chemically diﬀerent from native LDL, is not recognized by most scavenger receptors but
by the LDL receptor, oxLDL is recognized by scavenger receptors, but not by the LDLR
(Levitan et al., 2010). LDL oxidation is known to be a critical factor in atherosclerosis
development. Macrophages are able to take up and degrade modiﬁed LDL, which results
in cholesterol accumulation. Foam cell formation can be inhibited by the down-regulation
of certain scavenger receptors (Levitan et al., 2010).
Treatment of ECs or macrophages with mmLDL results in induction of chemotactic and
proinﬂammatory proteins (Levitan et al., 2010). It is suggested that mmLDL exerts
its EC stimulating properties before fatty streak formation, since in established lesions
LDL modiﬁcation is advanced and monocyte attraction and migration is mediated by
chemotactic factors derived fom macrophages and SMCs rather then LDL (Berliner et al.,
1990).
The presence of oxLDL in atherosclerotic lesions has been reviewed by Witztum and
Steinberg (2001) and it is commonly accepted that oxidation takes place in the suben-
dothelial matrix, not in the circulation due to the precence of antioxidants in the latter.
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OxLDL has been shown to inhibit SR-B1 expression in Raw 264.7 macrophages and as
a result to down-regulate cholesterol ﬂux in a dose- and time-dependent manner (Han
et al., 2001).
Lipoprotein carbamylation
Carbamylation is the nonenzymatic modiﬁcation of protein by cyanate (OCN-) (see
ﬁg.1.6). The spontanous dissociation of urea to cyanate and ammonia results in an
elevation of cyanate. Isocyanic acid, the active isoform, irreversibly binds to the NH2
and N-terminal groups of amino acids (Kraus and Kraus, 2001; Basnakian et al., 2010).
Fig. 1.6: LDL carbamylation (Basnakian et al., 2010)
Carbamylation is mostly associated with a partial or complete loss of protein function
(Kraus and Kraus, 2001; Apostolov et al., 2005; Basnakian et al., 2010) and a signiﬁcant
elevation of protein carbamylation is present in uremia (281.5±46.9 mg/L cLDL in ESRD
patients compared with 86.1±29.7 mg/L cLDL in controls; p<0.001) (Kraus and Kraus,
2001; Apostolov et al., 2005).
Gonen et al. (1985) observed altered LDL function in CKD subjects and suggested the
possibility that LDL carbamylation might occur in vivo. In their study, uremic LDL and
cLDL showed similar properties of interacting with ﬁbroblasts. The diminished uptake of
these particles by ﬁbroblasts may increase the residence time within the subendothelial
region of the vessel wall, and therefore exert the atherogenic properties of uremic LDL
(Gonen et al., 1985).
It has been shown that cLDL induces various pathways of damaging endothelial and
vascular SMCs (Ok et al., 2005; Apostolov et al., 2007a), and furthermore ICAM-1
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and VCAM-1 expression of endothelial cells, which leads to attraction and adhesion
of monocytes (Apostolov et al., 2007b; Basnakian et al., 2010; Thorne et al., 1996,
a). Its cytotoxicity is similar to the one of uremic LDL, oxLDL and acLDL (Basnakian
et al., 2010). Basnakian et al. (2010) suggested that carbamylated LDL (cLDL) highly
contributes to the atherosclerotic process, especially in ESRD patients, as well as, cLDL
being the cause of uremic atherosclerosis and the link to CKD (Basnakian et al., 2010).
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2 Material and Methods
All reagents were purchased from Roth (Karlsruhe, Germany), Merck (Darmstadt, Ger-
many) or Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise.
All experiments (except cholesterol eux) involving THP-1 cells and human peripheral
blood monocytes were performed under sterile conditions using an air laminar ﬂow (MWG
AG Biotech, Ebersberg, Germany) and 24-well tissue culture plates (greiner-bio-one
cellstar®).
For all THP-1 and monocyte/HMDM experiments RPMI-1640 (Roswell Park Memorial
Institute cell culture medium, Biochrom AG, Berlin, Germany) was used as medium,
either
• unsupplemented (RPMI-UK),
• supplemented with 100 U/ml penicillin, 0,1 mg/ml streptomycin (PAA, Pasching,
Austria), 2mM glutamine (PAA, Pasching, Austria) (RPMI w/o FCS), or
• supplemented with 100 U/ml penicillin, 0,1 mg/ml streptomycin, 2mM glutamine
and 10% FCS (fetal calf serum, GIBCO, Carlsbad, CA, USA) (RPMI compl.).
2.1 Patients and Controls
Samples (20-30 ml of venous blood) were obtained from patients with CKD, selected
strictly according to the exclusion criteria shown in Table 3, after an overnight fast (pe-
diatric subjects, adult and dialysis patients). Within 2h after blood collection monocytes
were isolated under sterile conditions and treated as described under 3.2.1, serum was
aliquoted and stored at -20°C, lipoproteins were fractioned and also stored at -20°C..
All patients as well as pediatric controls were recruited at the Vienna General Hospital
(AKH Wien) in collaboration with the Dept. of Pediatrics of the Medical University of
Vienna (Medizinische Universität Wien - MUW), the Dept. of Pediatric Surgery (MUW)
and the Dept. of Internal Medicine III (MUW) per the following exclusion criteria for
patients with CKD:
• Proteinuria ≥ 1g/l
• DOQI < 3
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• BMI > 30kg/m²
• Clinical instablility or infection during the last three months
• Diabetes mellitus, liver disease
• Other conditions associated with secondary dyslipoproteinemia (such as hypothy-
roidism, trisomy 21)
• Treatment with growth hormone, lipid lowering drugs or immunosuppression
Controls (healthy, fasting volunteers) were carefully chosen and matched by sex, age
and BMI (see Table 3). Informed consent (see ﬁg. 6.1 and 6.2) was obtained from all
subjects. A speciﬁcation of the clinical characteristics of patients and controls can be
found in the addendum.
The study was approved by the Ethics Committee of the Medical University of Vienna
(protocol #511/2007).
Tab. 4: Patients data
sex age DOQI Creatinin (mg/dl) BMI
male female
n n mean sd mean sd mean sd mean sd
pediatric patients 10 2 11.1 5.2 3.75 .75 3.21*** 1.28 20.43 4.15
controls 9 3 11.0 4.8 . . .48 .19 16.98 3.27
adult patients 6 11 34.6 8.6 3.81 .75 3.79*** 3.02 22.65 3.51
controls 6 11 34.8 9.3 . . .78 .11 22.52 2.52
dialysis patients 8 6 36.7 10.2 . . 7.66*** 4.09 25.26 4.77
controls 8 6 35.5 9.5 . . .87 .14 24.20 3.10
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2.2 Cell Culture
2.2.1 Monocyte isolation and diﬀerentiation
Reagents:
• 0.18 M EDTA (ethylene diamine tetra-acetate), pH 8
• Ficoll Paque (GE Healthcare, Uppsala, Sweden)
• RPMI-UK
• RPMI w/o FCS
Fasting venous blood samples for preparation of EDTA plasma and serum were obtained
from adult subjects and were centrifuged at 620 g, 18°C, brake 0 for 10 minutes (Ep-
pendorf centrifuge 5810 R). Plasma and serum were removed under sterile conditions in
a laminar air ﬂow (MWG AG Biotech, Ebersberg, Germany), aliquoted and stored at ei-
ther +4°C or -20°C for further use. The plasma was replaced with RPMI-UK, blood and
RPMI-UK were mixed carefully using a plastic pipette. Ficoll Paque (density 1.077g/l)
was placed in a 15 or 50 ml tissue culture tube (depending on the sample volume; Ficoll
Paque : blood-RPMI-mix = 1 : 1), the blood-RPMI-mix was then slowly layered above.
After centrifugation at 320 g and 18°C for 30 minutes (brake 0) the upper layer, consist-
ing of RPMI-UK and blood platelets, was removed and the buﬀy coat was collected and
transferred in 10 or 50 ml tissue culture tubes containing 5 ml RPMI-UK per 4 ml of
initial blood sample. This was followed by two washing steps. The ﬁrst one was a cen-
trifugation at 320 g, 18°C, 10 min, brake 9, after which the medium was removed using
a Pasteur pipette. The cell pellet was resuspended in fresh RPMI-UK (5 ml RPMI-UK
per 4 ml of initial blood sample) and, in the second washing step, again centrifuged at
320 g, 18°C, 10 min, brake 9. Then the cell pellet was resuspended in RPMI w/o FCS
and the cell suspension was seeded in 6 wells (24-well plates, 1 ml cell suspension + 10%
autologous serum/well). After 2h incubation at 37°C to allow the cells to adhere to the
plate, medium was changed to 350 µl RPMI w/o FCS + 10% autologous serum/well.
For diﬀerentiation to macrophages medium was exchanged every 2-3 days (350 µl RPMI
w/o FCS + 10% autologous serum/well) for 7 days, eux experiments were performed
on day 8 after the isolation process. The cells were kept at 37°C + 5% CO2 in an CO2
- incubator (C150, Binder, Tuttlingen, Germany).
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2.2.2 THP-1  cells
THP-1 cells (TIB-202; LGC Standards) are a human non-adhesive monocytic leukemia
cell line and can be diﬀerentiated into macrophage-like cells with phorbol esters, such as
phorbol 12-myristate 13-acetate (PMA). This cell line is commonly used to study foam
cell formation in atherosclerosis development (Auwerx, 1991).
Reagents:
• RPMI compl.
• 810 µM PMA (phorbol 12-myristate 13-acetate)
THP-1 cells were kept in suspension in RPMI compl. at a concentration below 1x106cells/ml.
For the cholesterol eux experiments, cells were seeded in 6 wells of a 24-well-plate at
a concentration of 5*105cells/well and diﬀerentiated towards macrophages in 250 µl
RPMI-compl. containing 160 nM PMA for 3 days.
2.3 Bradford protein assay (Bradford, 1976)
Reagents:
• Bradford protein assay (BioRad Laboratories, Hercules, CA, USA)
• Albumin, bovine serum, BSA (Sigma-Aldrich, St. Louis, MO, USA)
The Bradford protein assay is a method to determine the protein content of a sample
(cell lysates, lipoproteins). By binding of Coomassie brilliant blue G-250 to protein a
shift in the absorbance maximum from 465 nm to 595 nm is caused and monitored
(Bradford, 1976). Therefore 20 µl of Bradford reagent were mixed with 10 µl (for THP-
1 macrophages) or 30 µl (for HMDM) cell lysate and combined with distilled water to
reach a ﬁnal volume of 100 µl. Each time the Bradford assay was performed, a standard
curve was prepared using 0, 1, 2, 4 or 6 µl BSA (c = 1mg/ml), 20 µl Bradford reagent
and the amount of distilled water needed to reach a ﬁnal volume of 100 µl. Absorbance
was measured at 595 nm using a microplate reader. (BioRad iMarkMicroplate Reader).
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2.4 Western blotting
Western blotting is a method for immunodetection of proteins with speciﬁc antibodies.
For separation of the proteins the cell lysates are loaded onto SDS (sodium dodecyl
sulfate) - polyacrylamide gels, and separation in the electric ﬁeld occurs according to the
molecular mass of the proteins. For immunodetection the proteins are blotted onto a
nitrocellulose membrane after electrophoretic separation and detected by using speciﬁc
antibodies.
For Western blotting of CD36 in monocyte/macrophage cell lysates, monocytes were
isolated from 2 healthy volunteers and seeded on three 24 well plates, 2 wells per person
on each plate, as described before under 2.2.1, and diﬀerentiated towards macrophages
with RPMI w/o FCS containing 10% autologous serum.
2.4.1 Cell lysates
Reagents:
• PBS buﬀer
 137 mM NaCl
 2.7 mM KCl
 1.5 mM KH2PO4
 8.1 mM Na2HPO4x 12 H2O pH 7.4
• Lysis buﬀer
 62,5 mM Tris
 8 M Urea
 20 mM EDTA
 20 mM EGTA (ethylene glycol tetra-acetate)
 10% Glycerol
 1% SDS
 pH 6.8
• Protease inhibitor cocktail (1:100; Sigma-Aldrich, catalog number: P8340)
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After a 2h incubation period the cells on plate 1 were washed 2 times with 300µl PBS
(on ice) and solubilized with 100µl lysis buﬀer and 1 µl protease inhibitor cocktail/well.
Then they were scraped with a rubber policeman, transfered to Eppendorf tubes (1.5
ml), soniﬁed for 2 seconds, incubated on ice for 1h and stored at -20°C.
Plate 2 was subject to the same procedure after 7 days, plate 3 after 9 days of incubation
during which medium (250 µl RPMI w/o FCS + 10% autologous Serum/well) was
changed every 2-3 days.
2.4.2 Gel preparation and electrophoresis
Reagents:
• 30% acrylamid (BIS) solution, 29:1
• gel buﬀer (3 M Tris-HCl, 0.3% SDS, pH 8.45)
• 10% ammonium persulfate (APS, Pharma Biotech) in aqua dest.
• TEMED (N,N,N',N'-tetramethylethylenediamine)
• electrophoresis buﬀer (25 mM Tris, 200 mM glycine, 1% SDS, pH 8.0)
• sample buﬀer (4x)
 100 µl glycerol
 90 µl Tris buﬀer (0,267 µM Tris-HCl, 8% SDS, pH 6.8)
 a dash of bromphenol blue (Amsersham Biosciences, Little Chalfont, UK)
 10 µl b-mercapto-ethanol (Amsersham Biosciences, Little Chalfont, UK)
 sample buﬀer was always prepared just before use
The protein content of the samples was determined with the Bradford assay (Bradford,
1976) as described before, and the protein concentration of the samples was equaled by
adding PBS buﬀer. To each sample 4 µl of sample buﬀer were added, the mixture was
vortexed and incubated at 40°C for 30 minutes to denature the proteins.
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Tab. 5: Protocol of SDS-page gel (0,75mm) preparation
8% 4%
H2O bidest. 1.6ml 1.1ml
30% Acrylamide/Bis Solution 1.1ml 0.3ml
3 M Tris-HCl, pH 8,45; 0.3% SDS 1.3ml 0.7ml
10% APS 30µl 20µl
TEMED 3µl 2µl
For gel electrophoresis the Mini-PROTEAN®3 Cell (Bio-Rad, Hercules, CA, USA) sys-
tem was used. The corresponding glass plates (72 x 100 mm), suitable for a gel thickness
of 0.75 mm, were washed with 70% ethanol prior to use and placed in the gel cassette
according to the manufacturer's instructions.
Preparation of the running gel (8%) and the stacking gel (4%):
All of the components listed in table 5 were mixed in a clean tube, except for 10% APS
and TEMED which were added just before the pouring of the gel. After adding the
last two components the gel was poured immediately and covered with 30% isopropanol
to prevent it from drying. 30 minutes later the isopropanol was removed, the stacking
gel (prepared using the same mixing technique as for the running gel) was poured over
the now polymerized running gel and the comb was inserted to form the slots. After
additional 30 minutes the gel was ready for sample application.
Therefore the gel cassettes were moved to the electrophoresis chamber, which was ﬁlled
with electrophoresis buﬀer. After that, the comb was removed and the slots rinsed using
electrophoresis buﬀer. Equal amounts of the samples were loaded into the slots and a
protein ladder (PageRuler Prestained Protein Ladder, Fermentas, Burlington, Canada)
was added in a slot at the side of the gel. Electrophoresis was performed at 180 Volt
and 4°C for 80 minutes.
2.4.3 Western blotting
Reagents:
• transfer buﬀer (25 mM Tris, 200 mM glycine, 1% SDS, 20% methanol, pH 8.3)
• Ponceau S stain (1% Ponceau, 30% trichloracetic acid, 30% sulfosalicylic acid)
• TBS buﬀer (200 mM Tris base, 1.45 M NaCl, pH 7.4)
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• washing buﬀer (1 x TBS, 0.1 % TWEEN 20)
Tab. 6: Assembly of the transfer sandwich components
sponge
Whatman paper
nitrocellulose membrane
gel
Whatman paper
sponge
After electrophoresis the transfer sandwich was composed as described in table 6 and
placed in a Mini-Trans-Blot®Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA,
USA). The Sponges, the Whatman ﬁlter paper, as well as the nitrocellulose membrane
were steeped in transfer buﬀer before assembly to the sandwich. By rolling over the
Whatman paper with a glass pipette the formation of air bubbles between the gel and
the nitrocellulose membrane was avoided. The transfer sandwich, as well as a cooling
block were then inserted in the Blotting apparatus. The transfer was conducted at a
constant current of 0.4 Ampere for 45 minutes at 4°C. This was followed by staining of
the nitrocellulose membrane with Ponceau S for 10 minutes, cutting of the nitrocellulose
membrane according to the protein sizes and washing with washing buﬀer.
2.4.4 Immunodetection
Reagents:
• Washing buﬀer (1 x TBS buﬀer, 0,1% TWEEN 20)
• Blocking buﬀer (5% (w/v), non-fat, dry milk in washing buﬀer)
• Primary antibodies
 anti-b-actin (Sigma): mouse IgG2A, 1:5000
 anti-CD36 (Santa Cruz): mouse IgM, 1:150
• Secondary antibodies (diluted 1:10000 in blocking buﬀer)
 Goat anti-mouse IgG-HRP conjugate
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 Rabbit anti-mouse Ig-HRP
• Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA)
For blocking of nonspeciﬁc sites the nitrocellulose membrane was incubated with blocking
buﬀer at room temperature for 1 hour while shaking on a Belly Dancer undulating
orbital shaker, then washed two times with washing buﬀer and incubated on a Belly
Dancer undulating orbital shaker with primary antibody at 4°C overnight. An exception
was the nitrocellulose for detecting CD36 which was blocked with 3% BSA in TBS-T.
The next morning the blots were washed 3 times (each time for 10 minutes) with washing
buﬀer while shaking on a Belly Dancer undulating orbital shaker and then incubated
with secondary antibody for 1 hour at room temperature - again on a Belly Dancer
undulating orbital shaker. The same washing procedure (3 times, 10 minutes) was
applied one more time, then the blots were ready for imaging.
Therefore, the Super Signal West Pico Chemiluminescent Substrate was applied to the
nitrocellulose membrane according to the manufacturer's instructions, incubated for 5
minutes at room temperature and eventually placed in the ChemiImager 4400 (Biozym,
Hannover, Germany) for detection. Quantiﬁcation was carried out using the AlphaEase
FC software (Alpha Innotech Corporation, CA, USA).
2.5 Lipoprotein isolation and fractionation
Reagents:
• Potassium bromide (KBr)
• Dialysis buﬀer (0.9 % NaCl, 0.1% EDTA, pH 7.4)
For separating the lipoprotein fractions (VLDL, LDL, HDL) according to density we used
sequential ﬂotation ultracentrifugation (Havel et al., 1955). Therefore the amount of
KBr needed was calculated using the formula below:
gKBR = V (sample)∗density final−density initial
1−(0,312∗density final)
DPlasma = 1,006; DVLDL = 1,02; DLDL = 1,07; DHDL = 1,22 [mg/ml]
First, the density was adjusted for isolating VLDL and the samples centrifuged at
200,000xg at 4°C for 24h in a Optima L-100 XP ultracentrifuge using a 55.2 Ti ro-
tor (Beckmann-Coulter, Brea, CA, USA). The VLDL fraction was removed, the density
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of the remaining volume adjusted for LDL, and the ultracentrifugation was repeated.
The procedure was repeated a third and fourth time for HDL. The lipoprotein fractions
obtained were dialysed against (3x for 24h) using dialysis buﬀer (0.9 % NaCl, 0.1%
EDTA, pH 7.4) for removing KBr. Afterwards the protein content of the lipoprotein
fractions was determined with the Bradford Assay (described later).
2.6 Lipoprotein modiﬁcation
Reagents:
• 2 mM copper sulfate (CuSO4)
• 50 mM EDTA
• potassium cyanate (KCNO)
• phosphate (Na2HPO4)
• NICK-column (Sephadex G-50, Amersham Biosciences)
• saturated sodium-acetate
• acetic anhydride
• Dialysis buﬀer for acetylated LDL
Acetylated LDL
1 ml LDL (c = 2 mg/ml) and 1 ml saturated sodium-acetate were stirred on ice while
adding 2 µl of acetic anhydride every 10 minutes (5 times) followed by additional 30
minutes of stirring on ice and 24 h dialysis at 4°C to remove excess acetic anhydride.
Carbamylated LDL
LDL (c = 2 mg/ml), 20 mg/ml KCNO and 50 mM Na2HPO4- were incubated for 4 h at
37°C, then passed over a NICK-column to remove KCNO (100 µl to column, rinsed with
400 µl PBS, eluted with 400 µl PBS). The concentration of LDL after this procedure
was about 0.5 mg/ml.
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Minimally modiﬁed LDL
LDL (c = 2 mg/ml) was passed over a NICK-column to remove EDTA which has
the ability to build complexes with CuSO4 and to inhibit LDL oxidation by CuSO4.
Afterwards, 5 µM CuSO4 was added and LDL (c = 0.5 mg/ml) was incubated for 2 h
at 37°C. Then 50 µM EDTA was added to stop the reaction of CuSO4 and LDL.
Native LDL
Native LDL at a concentration of 2 mg/ml was passed over a NICK-column to ensure it
had undergone the same procedure as the modiﬁed LDLs. Concentration of LDL after
this procedure was about 0.5 mg/ml.
After modiﬁcation the lipoproteins were passed through a 0.45µm sterile ﬁlter. In most
cases preparations of 400µl per modiﬁcation were suﬃcient for the experiments.
2.7 Cholesterol eux Experiments
Reagents:
• [1,2-³H(N)-] Cholesterol (1 µCi/µl, Perkin Elmer, Waltham, MA, USA)
• Ready Safe Scintillation cocktail (Beckman Coulter)
• Bioﬂuor Plus (Perkin Elmer) (after the stop of production of Ready Safe Scintil-
lation Cocktail)
• PBS
• RPMI-UK
• HDL
• Serum
• LXR-Agonist (10 mM Liver-X-Receptor agonist, T0901317)
• acLDL
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24h prior to eux experiments THP-1 macrophages as well as HMDM were trace-labeled
with [³H]-Cholesterol (0.25 µCi/ml, 2 µl/well for THP-1 cells, 1,5 µl/well for HMDM, in
24-well-plates). Simulatneously, acLDL (50 µg/ml) and LXR-agonist (3 µM) was added
to load the cells with cholesterol and to maximize cholesterol eux by upregulating
ABCA-1 and ABCG-1 expression. This faciliates the detection of diﬀerences in the
acceptor properites of serum or HDL from patients and controls.
To start the experiment the cells were washed twice with 300 µl PBS (37°C) and equi-
librated with RPMI-UK (250µl/well) at 37°C for 2h. Then medium was removed and
the cells were again washed twice with 300 µl PBS (37°C). Afterwards, the cells were
incubated with medium (250 µl RPMI-UK/well) containing 10 µg/ml HDL, 1% serum,
apoA-I at diﬀerent concentrations, or no additional substances for 6h. After this pe-
riod the supernatant was removed and centrifuged at 1750 rpm and 4°C for 10 minutes
(Eppendorf centrifuge 5403). 150 µl of supernatant were mixed with 13 ml scintillation
cocktail and counted in a beta counter (Tri-Carb 2800 TR; Perkin Elmer).
The remaining cells were washed twice with 300 µl PBS (37°C) and 250 µl NaOH (0,1 M)
were added for cell lysis (room temperature, 45 min). 150 µl of cell lysates were mixed
with 13 ml scintillation cocktail and counted in a beta counter (Tri-Carb 2800 TR; Perkin
Elmer). The protein content of cell lysates was determined with the Bradford assay, as
described before.
Eux was calculated as percentage radioactivity in the media divided by the amount of
radioactivity in cell lysates and media using following formula:
%Efflux = 100∗cpm(supernatant)
cpm(media+lysates)
In every experiment, also eux to medium only with no additional substances was mea-
sured, then substracted as a background from the counts for serum, HDL and apoA-I
respectively, to exclude the inﬂuence of other factors probably present in the medium
that might aﬀect cellular cholesterol eux.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5.00 (GraphPad Software, San
Diego, CA, USA) and SPSS 11.5.1.0 (IBM, Somers, NY, USA). Data on serum lipids,
serum apoproteins and HDL composition were provided by Tatjana Stojacovic (Dept.
of Laboratory Medicine - Medical University of Graz), and are summarized in table 8 in
detail.
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Macrophage cholesterol eux is the ﬁrst step of reverse cholesterol transport and es-
sential for cholesterol homeostasis. HDL exerts its antiatherogenic properties mainly
by acting as an acceptor for cellular cholesterol, which is exported from cells via several
pathways. Among them are the ABCA1 mediated eux to apoA-I, as well as the ABCG1
or SR-B1 mediated eux to HDL, which constitute the primary step of the transport of
cellular cholesterol - RCT - from peripheral tissues back to the liver for excretion via bile
and feces (Vergeer et al., 2010).
In CKD the composition of HDL is altered and also HDL function and RCT may be af-
fected, the risk of developing atherosclerosis is increased signiﬁcantly and CVD mortality
is excessively high (Kwan et al., 2007; Oh et al., 2002; Schiﬀrin et al., 2007).
The aim of this thesis was to study the cholesterol acceptor capacity of serum and HDL
obtained from adult and pediatric CKD patients and dialysis patients, as well as the
cholesterol eux capacity of HMDM isolated from the study participants and healthy,
matched controls.
3.1 Cholesterol eux from THP-1 macrophages
THP-1 cells can be diﬀerentiated into macrophage-like cells and therefore are commonly
used to study foam cell formation in atherosclerosis development (Auwerx, 1991). THP-
1 cells were treated as described in the material and methods section (see 2.2.2). 24h
prior to the eux experiments the THP-1 macrophages were incubated with acLDL
(50 µg/ml) and trace-labeled with [³H]-cholesterol (1µCi). A synthetic LXR-agonist
(T0901317, 3 µM) was added to maximize cholesterol eux by upregulating ABCA1
and ABCG1 expression. Eux was performed for 6 hours to 1% serum and 10 µg/ml
HDL.
3.1.1 Inﬂuence of in vitro modiﬁed LDL on the cholesterol eux capacity
of THP-1 macrophages
For measuring the inﬂuence of in vitro modiﬁed LDLs on cellular cholesterol eux capac-
ity the THP-1 cells were diﬀerentiated towards macrophages and preincubated with either
bovine serum albumin (BSA), nLDL, cLDL or mmLDL (50 µg/ml) for 48h. 24h prior to
the eux experiment the THP-1 macrophages were trace-labeled with [³H]-cholesterol
(1µCi) and treated with LXR-agonist (T0901317, 3 µM). Eux was measured to 1%
serum or 10µg/ml HDL, obtained from healthy volonteers, after 6 hours.
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Fig. 3.1: Inﬂuence of in vitro modiﬁed LDLs on the cholesterol eux capacity of THP-1
macrophages
THP-1-cells were seeded at a density of 5*105cells/well, diﬀerentiated in 350 µl RPMI-compl. containing
160 nM PMA for 3 days and preincubated with either BSA, nLDL, cLDL or mmLDL 48h prior to the
eux experiments. 24h prior to eux experiments cells were trace-labeled with [³H]-Cholesterol (1µCi).
Each bar represents the mean ± SD, n=6. The results are expressed as % eux. Statistical signiﬁcance
was analyzed using an unpaired t-test (p<0.05 *, p<0.01 **).
cholesterol eux after preincubation with mmLDL was increased signiﬁcantly compared to BSA
(p<0.05), nLDL (p<0.01) and cLDL (p<0.01) and was signiﬁcantly higher to serum than to HDL
(p<0.001) except in mmLDL.
cholesterol eux to serum was signiﬁcantly increased after preincubation with mmLDL
compared to BSA , nLDL and cLDL respectively (mmLDL: 48.5±14.1 compared to BSA
(31.5±8.9; p<0.05), nLDL (27.3±4.2; p<0.01), cLDL (25.1±5.6; p<0.01)).
Svensson et al. (2005) reported SR-B1 to be upregulated under the inﬂuence of mmLDL,
which might be an explanation for the enhanced cholesterol eux to serum induced by
mmLDL in this experiment.
The results on cholesterol eux to HDL did not show a signiﬁcant diﬀerence, probably
due to the high standard deviation of the data obtained after mmLDL incubation.
3.1.2 Cholesterol acceptor capacity of apoA-I
To test the cholesterol acceptor capacity of apoA-I at diﬀerent concentrations as well as
the conditions for preincubation of THP-1 cells with human serum and to determine the
cholesterol eux capacity to apoA-I and HDL, THP-1 cells were diﬀerentiated towards
macrophages and preincubated with 10% human serum obtained from healthy volunteers
(1 male, 1 female) for 2 days. 24h prior to the eux experiment the THP-1 macrophages
were trace-labeled with [³H]-cholesterol (1µCi). Eux was measured to serum (1%) and
HDL (10 µg/ml), obtained from healthy volunteers, or apoA-I (10, 25, 50 µg/ml).
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Fig. 3.2: Cholesterol acceptor capacity of apoA-1
THP-1-cells were seeded at a density of 5*105cells/well, diﬀerentiated in 350 µl RPMI compl. containing
160 nM PMA for 3 days, then preincubated with 10% human serum for 3 days. 24h prior to eux
experiments cells were trace-labeled with [³H[-Cholesterol (1µCi). The bars for serum (1%), HDL (10
µg/ml) and apo-A1 (10, 25 µg/ml) represent the mean ± SD, n=8, for apoA-I (50 µg/ml) n=4. The
results are expressed as % eux.
cholesterol eux to serum was signiﬁcantly higher compared to HDL and apoA-I at three diﬀerent
concentrations.
No diﬀerence could be observed in eux to HDL and apoA-I , neither in THP-1 treated
with male serum, nor in THP-1 treated with female serum, nor taken together. Also,
the cholesterol eux to the three diﬀerent concentrations of apoA-I did not diﬀer.
Similar ﬁndings were obtained in HMDM (see ﬁg. 3.2.2).
3.1.3 Inﬂuence of uremic serum on cholesterol eux capacity of THP-1
macrophages
To study the inﬂuence of uremic serum on the cholesterol eux capacity of THP-1
macrophages, THP-1 cells were diﬀerentiated towards macrophages and incubated with
10% pooled serum from adult CKD patients or healthy, matched controls for 48h. Eux
was performed to control serum, HDL and apoA-I.
When cholesterol eux to 3 diﬀerent concentrations of apoA-I was measured in a previ-
ous experiment (see ﬁg 3.2), no diﬀerence could be observed. Hence, for this experiment,
it was decided to solely use the 10 µg/ml preparation.
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Fig. 3.3: Inﬂuence of uremic serum on the cholesterol eux capacity of THP-1
macrophages
THP-1-cells were seeded in 24-well-plates at a densitiy of 5*105cells/well, diﬀerentiated towards
macrophages and incubated with 10% pooled serum from uremic patients or controls, for 2 days.
24h prior to eux experiments cells were trace-labeled with [³H]-cholesterol (1µCi). Each bar repre-
sents the mean ± SD, n=3. The results are expressed as % eux. Statistical signiﬁcance was analyzed
using an unpaired t-test (p<0.05 *).
cholesterol eux to HDL was signiﬁcantly diminished in patients (p<0.05), eux to serum and apoA-I
was not altered.
The cholesterol eux capacity of THP-1 macrophages incubated with serum obtained
from adult CKD patients to HDL was decreased signiﬁcantly (p<0.05; patients 7.00±1.04,
controls 10.73±1.72) while eux to serum and apoA-I did not diﬀer between pa-
tients (serum 19.37±1.94; apoA-I 5.17±0.60) and controls (serum 20.67±0.38; apoA-I
3.40±1.85).
3.1.4 Cholesterol acceptor capacity of uremic serum and HDL for cellular
cholesterol exported by THP-1 macrophages
Next, the inﬂuence of CKD on the cholesterol acceptor capacity of serum or HDL was
studied. Therefore, THP-1 cells were diﬀerentiated towards macrophages and cholesterol
eux to 1% individual serum samples and 10 µg/ml individual HDL was measured. The
patient's serum and HDL samples of adult CKD patients, dialysis patients and matched
controls were analyzed individually.
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Fig. 3.4: Cholesterol acceptor capacity of uremic serum and HDL for cellular cholesterol
exported by THP-1 macrophages
THP-1-cells were seeded at a density of 5*105cells/well and diﬀerentiated in 250 µl RPMI-compl.
containing 160 nM PMA for 3 days. 24h prior to eux experiments cells were incubated with acLDL
(50 µg/ml), LXR-agonist (T0901317, 3 µM) and trace-labeled with [³H]-Cholesterol (1µCi). Statistical
signiﬁcance was analyzed using an unpaired t-test (p<0.05 *, p<0.01 **).
cholesterol eux to serum isolated from adult patients with CKD stage 3-5 was increased signiﬁcantly
(p<0.05; C) and diminished signiﬁcantly in dialysis patients (p<0.01; E). Eux to HDL was increased
in pediatric patients (p<0.05; B) while it was not altered in adult CKD patients stage 3-5 or dialysis
patients (D, F).
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While it could be shown that the cholesterol acceptor capacity of serum of adult patients
increases signiﬁcantly (patients 49.68±4.34; controls 45.86±5.95; N=17; p<0.05; ﬁg.
3.4, C), in dialysis patients the opposite occurred, namely a signiﬁcant decrease (patients
31.73±4.22; controls 36.85±3.20; p<0.01; ﬁg. 3.4, E). In eux experiments to 10 µg/ml
HDL no diﬀerence could be shown, in both, adult CKD patients stage 3-5 and dialysis
patients, and controls respectively (ﬁg. 3.4, D, F).
A signiﬁcant increase in cholesterol eux to HDL could be observed in pediatric patients
(patients 8.71±3.52, N=12; controls 4.71±4.00; p<0.05, ﬁg. 3.4, B), while in eux to
serum no diﬀerence was found in eux to serum (ﬁg. 3.4, A).
Fig. 3.5: Cholesterol acceptor capacity of uremic serum and HDL for cellular cholesterol
exported by THP-1 macrophages-overview
THP-1-cells were seeded at a concentration of 5*105cells/well and diﬀerentiated in 250 µl RPMI-compl.
containing 160 nM PMA for 3 days. 24h prior to eux experiments cells were incubated with acLDL
(50 µg/ml), LXR-agonist (T0901317, 3 µM) and trace-labeled with [³H]-Cholesterol (1µCi). Statistical
signiﬁcance was analyzed using an unpaired t-test (p<0.05 *, p<0.01 **; pediatric patients/controls:
n=12 per group, adult patients/controls: n=17 per group; dialysis patients/controls: n=14 per group).
Whereas serum-HDL (mg/dl) was found to be diminished signiﬁcantly in serum of pedi-
atric patients and adult dialysis patients (pediatric controls 48.5±9.9, pediatric patients
32.2±13.2; p<0.01; dialysis controls 53.2±14.1, dialysis patients 36.8±9.3; p<0.01;
tab. 8), the apoA-I serum levels (mg/dl) of pediatric patients were not altered. Con-
trarily, in adult hemodialysis patients apoA-I levels were decreased signiﬁcantly (controls
166.6±29.8, patients 132.4±27.0; p<0.01; tab. 8). This might, at least to some ex-
tent, explain the signiﬁcantly reduced cholesterol acceptor capacity of serum in dialysis
patients (Fig. 3.5).
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Fig. 3.6: Cholesterol eux from THP-1 cells
cholesterol eux from THP-1 cells to HDL of all adult subjects signiﬁcantly correlates with age (A;
R²=0.068 ; p=0.0461). cholesterol eux from THP-1 macrophages to serum isolated from adult
CKD stage 3-5 and dialysis patients positively correlates with apoA-I levels (B; R²=0.138; p=0.0398),
especially in the group of dialysis patients (C; R²=0.422; p=0.0088).
Cholesterol eux from THP-1 macrophages to HDL of all adult subjects signiﬁcantly
correlated with age (R²=0.068 ; p<0.05; ﬁg.3.6, A).
cholesterol eux to serum isolated from adult CKD and dialysis patients positively cor-
related with serum apoA-I levels (R²=0.138; p<0.05; ﬁg. 3.6, B), which was even more
distinct in the group of dialysis patients (R²=0.422; p<0.01; ﬁg. 3.6, C).
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3.2 Cholesterol eux from human monocyte-derived
macrophages (HMDM)
Macrophages play a major role in atherosclerosis development as they take up modiﬁed
LDL via scavenger receptors, which leads to foam cell formation, subsequent formation
of atherosclerotic lesions and CVD eventually (Lusis, 2000).
Much less is known about their ability to export cholesterol in this condition.
3.2.1 Western Blot Analysis
Cholesterol is taken up via SR-A1/2 and CD36 (Chmielewski et al., 2005). CD36 is
not present in peripheral blood monocytes, but generated during diﬀerentiation towards
macrophages. Thus, by scanning for the day during diﬀeretiation with the highest ex-
pression of CD36 it was possible to identify the most suitable time for [³H]-cholesterol
labelling and cholesterol eux and, more importantly, to prove that the cells used for the
subsequent experiments were fully diﬀerentiated human monocyte-derived macrophages.
Monocytes were isolated as described before (see 2.2.1) and diﬀerentiated towards
macrophages for 0, 7, or 9 days under 250 µl RPMI w/o FCS with 10% autologous
serum, then Western Blot Analysis was performed. The highest expression of CD36, was
observed on day 7 (data not shown). The cells were trace-labeled with [³H]-Cholesterol
(1µCi) on that day and eux to serum (1%) or HDL (10µg/ml) was performed on day
8.
3.2.2 Cholesterol eux from HMDM
To determine whether in contrast to the experiments in THP-1 macrophages in HMDM
a diﬀerence can be detected in cholesterol export to HDL and apoA-I, cholesterol eux
from HMDM was measured to diﬀerent acceptors (see section 3.1.2). Again, two con-
centrations of apoA-I (10 µg/ml and 25 µg/ml) were used according to the results of
the experiment in THP-1 macrophages, which did not show a diﬀerence in eux to the
diﬀerent concentrations of apoA-I (see ﬁg. 3.2).
Monocytes were isolated from blood obtained from two healthy, fasting volonteers (one
male, one female), as described before, and diﬀerentiated towards macrophages for 7
days under 250 µl RPMI w/o FCS containing 10% autologous serum. Eux experiments
were performed on day 8.
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Fig. 3.7: Cholesterol eux from HMDM
Monocytes were isolated from blood samples obtained from two healthy, fasting volonteers (one male,
one female), mixed and diﬀerentiated towards macrophages under RPMI w/o FCS with 10% pooled,
autologous serum for 7 days. 24h prior to eux experiment the cells were trace-labeled with [³H]-
cholesterol (1µCi). cholesterol eux was measured on day 8 to 1% healthy serum, 10 µg/ml healthy
HDL or apoA-I (10 µg/ml, 25 µg/ml). Each bar represents the mean ± SD, n=4. The results are
expressed in % eux. Statistical signiﬁcance was analyzed using an unpaired t-test (p<0.05 *, p<0.01
**, p<0.001 ***).
cholesterol eux from HMDM to serum was signiﬁcantly higher than to HDL (p<0.0001) and two
diﬀerent concentrations of apoA-I (p<0.05 to 10 µg/ml; p<0.01 to 25 µg/ml).
The results obtained in THP-1 cells could be conﬁrmed in HMDM: there was no signif-
icant diﬀerence in eux to HDL and apoA-I at both concentrations.
3.2.3 Inﬂuence of in vitro modiﬁed LDL on the cholesterol eux capacity
of HMDM
To investigate the inﬂuence of in vitro carbamylated LDL on cholesterol eux from
HMDM to control serum and HDL, blood samples were obtained from two healthy,
fasting volonteers, monocytes were isolated as described before (see 2.2.1) and diﬀer-
entiated towards macrophages for 7 days under 250 µl RPMI w/o FCS containing 10%
autologous serum. Two days before the eux experiment the HMDM were preincubated
either with nLDL or cLDL. 24h prior to the cholesterol eux experiment the HMDM
were trace-labeled with [³H]-cholesterol (1µCi) and eux was performed on day 8 to 1%
serum and 10 µg/ml HDL obtained from healthy volunteers.
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Fig. 3.8: Inﬂuence of in vitro modiﬁed LDL on the cholesterol eux capacity of HMDM
Monocytes were isolated from blood samples obtained from two healthy, fasting volonteers (one male,
one female), mixed and diﬀerentiated towards macrophages under RPMI w/o FCS with 10% pooled,
autologous serum for 7 days. The cells were preincubated with either nLDL or cLDL 48h prior to the
eux experiment. 24h prior to eux experiment the cells were trace-labeled with [³H]-Cholesterol
(1µCi). cholesterol eux was measured on day 8 to 1% healthy serum or 10 µg/ml healthy HDL. Each
bar represents the mean ± SD, n=6. The results are expressed in % eux.
No alterations in cholesterol eux to nLDL and cLDL could be observed.
There was no signiﬁcant diﬀerence in the cholesterol eux capacity of HMDM treated
with either nLDL or cLDL, neither to serum (nLDL 24.55±3.65; cLDL 21.78±1.68)
nor HDL (nLDL 9.88±1.99; cLDL 9.83±1.97), although eux to serum from HMDM
incubated with cLDL was slightly lower. This is consistent with the results from previous
experiments in THP-1 macrophages (see ﬁg. 3.1), where eux neither to serum nor to
HDL was altered, no matter if the cells were incubated with nLDL or cLDL.
3.2.4 Inﬂuence of uremia on the cholesterol eux capacity of HMDM
To compare the eux capacity of HMDM of adult CKD patients, dialysis patients and
healthy controls, blood samples were obtained from patients recruited at the Dept. of
Internal Medicine III of the Medical University of Vienna (MUW) and controls carefully
matched by sex and age (for details see 2.1 Patients and controls).
Monocytes were isolated within 2h after sample collection and diﬀerentiated towards
macrophages with RPMI w/o FCS containing 10% autologous serum for 7 days (24-
well-plates, 6 wells/sample). cholesterol eux experiments were performed on day 8
using 1% healthy serum and 10 µg/ml HDL obtained from healthy donors.
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Fig. 3.9: Inﬂuence of uremia on the cholesterol eux capacity of HMDM
Monocytes were isolated from venous blood samples and diﬀerentiated towards macrophages under
RPMI w/o FCS with 10% autologous serum for 7 days. 24h prior to eux experiments the cells were
trace-labeled with [³H]-Cholesterol (1µCi). cholesterol eux was measured on day 8 to 1% serum or
10 µg/ml HDL obtained from healthy volonteers. The results are expressed in % eux. Statistical
signiﬁcance was analyzed using an unpaired t-test (p<0.05 *, p<0.01 **, p<0.001 ***).
In adult CKD patients, no diﬀerence in cholesterol eux capacity of HMDM to control
serum or HDL could be observed (ﬁg. 3.9, A, B), whereas in dialysis patients a signiﬁcant
increase in eux capacity to control serum as well as to control HDL could be shown
(serum: patients 39.95±19.73; controls 17.74±8.36; p<0.001; ﬁg. 3.9, C; HDL: patients
33.50±22.23; controls 15.74±7.20; p<0.01; ﬁg. 3.9, D).
These observations are in contrast to the results obtained for cholesterol acceptor ca-
pacity of serum or HDL using THP-1 cells (see Fig. 3.5), where the acceptor capacity
of serum of dialysis patients was diminished signiﬁcantly (patients 31.73±4.22; controls
36.85±3.20; p<0.01; ﬁg. 3.4, E) and the acceptor capacity of serum of adult CKD
patients was increased (patients 49.68±4.34; controls 45.86±5.95; p<0.05; ﬁg. 3.4, C)
compared to healthy controls.
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Similarily, the signiﬁcant increase in the cholesterol eux capacity of HMDM of dialysis
patients to HDL (p<0.01; ﬁg. 3.9, D) is in contrast to the results of cholesterol acceptor
capacity of serum or HDL measured using THP-1 macrophages (see ﬁg. 3.4, F), where
no diﬀerence could be shown.
Fig. 3.10: Inﬂuence of uremia on the cholesterol eux capacity of HMDM-overview
Monocytes were isolated from blood samples and diﬀerentiated towards macrophages under RPMI w/o
FCS with 10% autologous serum for 7 days. 24h prior to eux experiments the cells were trace-labeled
with [³H]-Cholesterol (1µCi). cholesterol eux was measured on day 8 to 1% serum or 10 µg/ml HDL
obtained from healthy volonteers. The results are expressed in % eux. Statistical signiﬁcance was
analyzed using an unpaired t-test (p<0.05 *, p<0.01 **, p<0.001 ***).
The cholesterol eux capacity of HMDM to control serum was increased signiﬁcantly in dialysis patients
compared to adult patients (p<0.05). Also, cholesterol eux from HMDM to control HDL was increased
signiﬁcantly compared to adult patients (p<0.05).
Furthermore, the cholesterol eux capacity of HMDM obtained from dialysis patients
to control serum and HDL was increased signiﬁcantly compared to adult CKD patients
(serum: adult patients 20.1±12.4, dialysis patients 40.0±19.7, p<0.05, ﬁg.3.10, A;
HDL: adult patients 13.7±12.2, dialysis patients 33.5±22.2, p<0.05, ﬁg. 3.10, B).
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Fig. 3.11: cholesterol eux from HMDM
cholesterol eux from HMDM of dialysis patients to control HDL has a tendency to decrease with age
(A; n.s.). In adult patients a negative correlation of cholesterol eux capacity of HMDM and cholesterol
acceptor capacity of control serum (B; R²=0.281; p=0.0112) and HDL (C; R²=0.372; p=0.0026) could
be shown.
In HMDM no signiﬁcant correlation between cholesterol acceptor capacity of HDL and
age could be found although there might be a tendency of cholesterol eux capacity
to decrease with increasing age in dialysis patients (R²=0.281; p=0.0624; ﬁg.3.11, A).
This could not be observed in pediatric or adult patients or eux to serum respectively.
In adult patients, a negative correlation between the cholesterol acceptor capacity and
the cholesterol eux capacity from HMDM (R²=0.281; p<0.05; ﬁg. 3.11, B) and HDL
(R²=0.372; p<0.01; ﬁg. 3.11, C) could be shown, which leads to the speculation that
the cells try to compensate a diminished cholesterol acceptor capacity with a higher rate
of cholesterol eux.
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3.2.5 Capacity of pediatric, uremic serum and HDL to act as an acceptor
for cellular cholesterol exported by healthy HMDM
Attempting to validate the data obtained from the experiments in THP-1 macrophages
(described in section 3.1.4, ﬁg. 3.4 A) for HMDM, monocytes were isolated and diﬀer-
entiated towards macrophages under RPMI w/o FCS containing 10% autologous serum
for 7 days. Eux was performed on day 8 to 1% pooled serum and 10 µg/ml pooled
HDL.
Fig. 3.12: Capacity of pediatric, uremic serum and HDL to act as an acceptor for cellular
Cholesteroleuxed from healthy HMDM
Monocytes were isolated from blood samples obtained from a healthy volonteer (female) and diﬀeren-
tiated towards macrophages under RPMI w/o FCS with 10% autologous serum for 7 days. 24h prior to
eux experiments the cells were trace-labeled with [³H]-Cholesterol (1µCi). cholesterol eux was mea-
sured on day 8 to 1% pooled serum or 10 µg/ml pooled HDL obtained from pediatric patients/controls.
Each bar represents the mean ± SD, n=5. The results are expressed in % eux.
The cholesterol eux capacity of THP-1 macrophages to serum or to HDL isolated from pediatric
patients was not altered signiﬁcantly.
The results for cholesterol eux from HMDM to either 1% pooled serum or 10 µg/ml
pooled HDL did not diﬀer signiﬁcantly (serum: patients 17.5±2.2; controls 19.9±2.0;
HDL: patients 14.3±2.8; controls 16.6±2.9), although the eux capacity of serum as
well as of HDL seems to be slightly diminished in patients. HDL serum levels (mg/dl)
were decreased in patients (p<0.01), while apoA-I serum levels (mg/dl) were not altered
signiﬁcantly compared to controls (see tab. 8).
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4 Discussion
Atherosclerosis, a chronic, progressive disease, is highly prevalent in chronic kidney dis-
ease (Chade et al., 2005). The risk for CKD patients to die from a CV cause is excessively
elevated, especially in children and young adults (Oh et al., 2002; Schiﬀrin et al., 2007).
The development of atherosclerosis in CKD is at least in part due to a disturbed choles-
terol balance in macrophages of the arterial wall.
In the context of CKD cellular cholesterol inﬂux into macrophages has been studied in
more detail than cholesterol eux. Cholesterol uptake from modiﬁed LDL is mediated
by the scavenger receptors SR-A1/2 and CD36 and their expression is elevated in CKD
patients (Chmielewski et al., 2005). It is known that CD36 is hardly expressed in mono-
cytes but that its protein expression increases with the grade of diﬀerentiation (Huh
et al., 1996). However, not only the state of diﬀerentiation, but also the presence of
cytokines and growth factors contributes to the CD36 expression (Han et al., 1997). The
expression of all three, SR-A1/2 and CD36, has been shown to be increased in blood
monocytes of CKD patients, which possibly contributes to the risk of developing severe
atherosclerosis. CD36 expression is even higher in dialysis than in CKD patients, yet, it
is not entirely clear if the enhanced expression is due to the longer duration of CKD or
to the impact of hemodialysis treatment (Chmielewski et al., 2005; Konishi et al., 1997).
Cellular cholesterol eux is part of a process called reverse cholesterol transport in which
excess cholesterol is removed from peripheral cells and transported back to the liver for
excretion (Lusis, 2000). The initial step of RCT is the cellular cholesterol eux to
apoA-I, the main apolipoprotein of HDL. Alterations in HDL composition (Kwan et al.,
2007; Marsche et al., 2008), as well as low HDL-cholesterol (Gonen et al., 1985) may
contribute to an impairment of RCT during CKD, which leads to an increased risk for
developing atherosclerotic disease (Cho, 2009). Thus, both the quantity and also the
quality of HDL are critical for adequate cholesterol eux (Chirinos et al., 2005; Cho,
2009), however, its exact role is still incompletely understood (Weichhart et al., 2012).
In addition to its role in reverse cholesterol transport Weichhart et al. (2012) showed
that control HDL is able to inhihbit inﬂammatory cytokine production, whereas HDL
obtained from ESRD patients had lost this property and, beyond that, even promoted the
production of inﬂammatory cytokines (Weichhart et al., 2012). This pathophysiological
mechanism is thought to enhance atherosclerosis development and may eventually lead
to fatal CV events (Oh et al., 2002; Schiﬀrin et al., 2007).
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This study aimed to investigate the cholesterol acceptor capacity of serum and HDL
obtained from adult and pediatric CKD patients, dialysis patients and healthy matched
controls, as well as the cholesterol eux capacity of HMDM isolated from the study
participants and healthy, matched controls.
The ﬁrst aim, to examine the cholesterol acceptor capacity of serum and HDL iso-
lated from the study participants, was investigated in experiments conducted in THP-1
macrophages as well as in HMDM.
To deﬁne the experimental conditions, ﬁrst the cholesterol acceptor capacity of diﬀerent
concentrations of apoA-I (10, 25, 50 µg/ml) was measured in THP-1 macrophages. No
diﬀerence was detected between the three apoA-I concentrations and HDL respectively
(ﬁg. 3.2).
The results from THP-1 macrophages could be veriﬁed in HMDM where, again, choles-
terol eux did not diﬀer when measured to HDL and apoA-I at two diﬀerent concen-
trations (10, 25 µg/ml; ﬁg. 3.7). Taking into account the fact that apoA-I is the major
apolipoprotein of HDL (Cho, 2009) the similar results in cholesterol acceptor capacity
of HDL and apoA-I observed in these experiments are explicable.
To examine the cholesterol acceptor capacity of uremic serum and HDL, eux was
measured from THP-1 macrophages to patient's and control's individual serum (1%)
and HDL (10 µg/ml) respectively. The cholesterol acceptor capacity of serum from adult
patients was increased signiﬁcantly (p<0.05; ﬁg 3.4, C), whereas in dialysis patients the
contrary, a signiﬁcant decrease (p<0.01), could be shown (ﬁg. 3.4, E). This might, at
least to some extent, be explained by the signiﬁcantly reduced concentration of serum
apoA-I in the dialysis patients of this cohort. ApoA-I is known to promote cellular
cholesterol eux via the ABCA1 pathway (Ohashi et al., 2005). Indeed, the cholesterol
acceptor capacity of serum isolated from adult CKD stage 3-5 and dialysis patients
positively correlated with the apoA-I level (mg/dl; p<0.05; ﬁg. 3.6, B), which was even
more distinct in the group of dialysis patients (p<0.01; ﬁg. 3.6, C). Also, pediatric CKD
patients did not show a diminished cholesterol accceptor capacity of serum compared to
controls, which might be due to the unaltered serum apoA-I concentration despite low
HDL.
Investigating the cholesterol eux to uremic and control HDL, a diﬀerence could exclu-
sively be observed in the group of pediatric subjects, where the patient's cellular choles-
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terol eux was increased signiﬁcantly (p<0.05; ﬁg. 3.4, B). Notably, the cholesterol
acceptor capacity of serum was not altered in this group. This again, might be related
to the serum apoA-I concentration which, in contrast to the serum HDL-C concentra-
tion, was not altered in pediatric CKD patients compared to controls. In an attempt to
conﬁrm these data using HMDM, cholesterol eux was measured from HMDM obtained
from a healthy adult volunteer to either 1% pooled serum or 10 µg/ml pooled HDL of
pediatric patients. In this experiment the cholesterol acceptor capacity of serum and
HDL was subtly higher in control subjects, but did not diﬀer signiﬁcantly (ﬁg. 3.11).
This is in contrast to the ﬁndings in THP-1 macrophages where eux to the patients
individual HDL preparations was found to be increased signiﬁcantly (p<0.05; ﬁg. 3.4,
B).
HDL synthesis and maturation are impaired during CKD and ESRD and as a consequence
HDL levels are diminished. It has been speculated that uremia renders HDL dysfunc-
tional by altering its composition and functionality. In 2000, Morena et al. showed
impaired atheroprotective eﬀects of HDL, functional and quantitative lipid abnormali-
ties, and increased susceptibility to LDL oxidation during hemodialysis, and furthermore,
an association between qualitative abnormalities of LDL during HD as well as a decrease
in HDL antioxitative properties (Morena et al., 2000). Moreover, an enhanced suscepti-
bility of HDL to lipid peroxidation, as well as a decrease of its antioxidant activity with
increasing age, has been shown (Berrougui et al., 2007).
In 2011 Holzer et al. investigated the proteomic proﬁle as well as the cholesterol acceptor
capacity of uremic HDL isolated from patients on maintenance hemodialysis and reported
that the altered composition of uremic HDL is linked to a diminished cholesterol eux
due to apoA-I, apoA-II and phospholipid depletion (Holzer et al., 2011a). This is in
contrast to our ﬁnding of an unaltered cholesterol acceptor capacity of HDL in a similar
patient group. Exclusion of diabetic patients in our study and the use of human THP-1
cells, rather than the mouse RAW267 macrophage line employed by Holzer et al, as
well as diﬀerences in the techniques for HDL isolation may explain these diﬀerences.
Moreover, it needs to be taken into account that the patients in the study of Holzer et
al. were clearly older than the controls.
In our study the cholesterol acceptor capacity of HDL from all adult subjects signiﬁcantly
decrased with age (p<0.05; ﬁg. 3.6, A). In dialysis patients there was a trend toward
a negative correlation of cholesterol eux capacity of HMDM and age, although this
result did not reach statistical signiﬁcance (p=0.0624; R²=0.2810; ﬁg. 3.11, A). The
exact mechanism of this process remains to be elucidated. Similarly, Berrougui et al.
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(2007) studied cholesterol eux from THP-1 and J774 macrophages to HDL obtained
from healthy, young and healthy, elderly subjects respectively, and showed a signiﬁcantly
diminished capacity of HDL from elderly subjects to promote cholesterol eux (Berrougui
et al., 2007).
Holzer et al. reported in 2011 that HDL carbamylated by myeloperoxidase (MPO) can
be found in the vessel wall. In SR-B1 overexpressing THP-1 cells they were able to
demonstrate that carbamylation of HDL in vitro results in net cholesterol uptake by
destabilizing the HDL/SR-B1-dependent balance of cholesterol inﬂux and eux, thereby
promoting the development of atherosclerosis in ESRD, where the urea-levels are ex-
tremely high. This eﬀect, however, could not be shown in non-transfected control cells
(Holzer et al., 2011b).
A very recent study by Weichhart et al. (2012) demonstrated an altered HDL protein
composition in ESRD patients. Surfactant protein-B (SP-B), ApoC-II, serum-amyloid A
(SAA), and alpha-1-microglobulin/bikunin precursor (AMBP) were found to be enriched
in ESRD patients compared to healthy controls. Moreover, Weichhart et al. found SB-P
in patients HDL exclusively. As they were able to detect SB-P and SAA in stage 4 CKD
patients as well, this indicates that the changes in HDL composition are not only due
to hemodialysis, as has been speculated before, but to uremia itself (Weichhart et al.,
2012). In healthy controls SB-P was not detectable at all, hence its plasma concentration
may be a novel biomarker for CKD progression as well as kidney failure, cardiovascular
morbidity and mortality (Weichhart et al., 2012) and chronic heart failure (Pasquale
et al., 2004).
After investigating the cholesterol acceptor capacity of THP-1 macrophages and HMDM,
we examined the eﬀect of LDL modiﬁcations occuring in CKD patients, namely carbamy-
lation and oxidation, on the cholesterol eux capacity of THP-1 macrophages.
In CKD subjects modiﬁed LDL are capable of stimulating CE accumulation in the
macrophages of the vessel wall (Gonen et al., 1985), which is a key event in atheroscle-
rosis development (Lusis, 2000). Especially carbamylated LDL has been shown to be re-
markably elevated in serum of ESRD patients (281.5±46.9 mg/l compared to 86.1±29.7
mg/l in controls; p<0.001) (Apostolov et al., 2005). It has been suggested that cLDL
holds a major part in the atherosclerotic process, especially in these patients (Basnakian
et al., 2010). Furthermore, Ok et al. (2005) showed that cLDL also damages human
coronary artery endothelial cells (HCAECs) in a dose- and time-dependent manner and
that it is remarkably elevated in hemodialysis patients (Ok et al., 2005).
OxLDL is commonly divided in two forms: minimally modiﬁed LDL and extensively oxi-
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dized LDL (oxLDL). While mmLDL is still recognized by the LDLR, oxLDL is recognized
by scavenger receptors, but not vice versa (Levitan et al., 2010).
To investigate the inﬂuence of in vitro modiﬁed LDL (nLDL, cLDL, mmLDL) on the
cholesterol eux capacity of THP-1 macrophages cholesterol eux to control serum
and HDL was measured. In these experiments the cholesterol eux capacity was found
to be signiﬁcantly increased in macrophages pretreated with mmLDL only, but not with
cLDL (p<0.01 vs. nLDL; ﬁg. 3.1).
In human monocyte-derived macrophages the inﬂuence of cLDL on the cholesterol eux
capacity of HMDM obtained from a healthy volunteer to control serum and HDL was in-
vestigated and compared to the inﬂuence of nLDL. The results did not show a signiﬁcant
diﬀerence (ﬁg. 3.8), which is consistent with the ﬁndings in THP-1 macrophages, where
an increase in eux was observed in macrophages pretreated with mmLDL exclusively
(ﬁg. 3.1).
These data are in agreement with the results of Svensson et al. (2005), who found SR-
B1, which promotes cellular cholesterol eux in peripheral tissues (Pagler et al., 2007),
to be upregulated under the inﬂuence of mmLDL (p<0.05) in HMDM of atherosclerosis
patients and healthy controls (Svensson et al., 2005).
Han et al. (2001) reported SR-B1 expression to be time-dependent in a murine macrophage
cell line (J774), when treated with oxLDL. They observed an increase in SR-B1 expres-
sion when oxLDL was added after 3 days in culture, but a decrease when added to fully
diﬀerentiated macrophages after 10 days in culture, which is in contrast to the results of
Hirano et al. (1999), who found SR-B1 to be markedly upregulated as the diﬀerentiation
of human monocytes to macrophages progresses (Han et al., 2001; Hirano et al., 1999).
In this study modiﬁed LDL was added to fully diﬀerentiated macrophages.
Cardinal et al. (2007) reported a down-regulation of ABCA1 and ABCG1 in human
coronary arterial endothelial cells (HCAEC), that had been treated with 20% uremic
plasma for 48 hours, which could lead to the speculation that eux to apoA-I should
be decreased in THP-1 macrophages incubated with uremic serum. This could not be
observed in our study (see ﬁg. 3.3). Still, eux to HDL was diminished signiﬁcantly in
THP-1 macrophages pretreated with uremic serum (p<0.05; ﬁg.3.3).
According to Maggi et al. (1994), who reported an increased level of oxLDL present
in CKD and Cardinal et al. (2007) who, as mentioned above, reported decreased levels
of ABCA1 and ABCG1 in HCAECs, the diminished cholesterol eux capacity to HDL
of THP-1 macrophages treated with uremic serum, could be explained. This is in full
contrast to the results of Hirano et al. (1999), according to which cholesterol eux
would be upregulated under the inﬂuence of oxidativly modiﬁed LDL and thus during
CKD where higher amounts of modiﬁed LDL are present.
49
Further research is needed to elucidate the underlying pathophysiological mechanisms.
Finally we studied the eﬀect of CKD on the cholesterol eux capacity of HMDM isolated
from adult CKD patients, dialysis patients and healthy, matched controls to control serum
and HDL.
In adult patients with CKD stage 3-5 as compared to controls no diﬀerence in cellular
cholesterol eux to serum or HDL could be observed. In dialysis patients, however,
a signiﬁcant increase in eux to serum and HDL respectively could be found (serum
p<0.001; HDL p<0.01; ﬁg. 3.9, B, D). In addition, eux to serum as well as to HDL
was signiﬁcantly augmented in dialysis patients compared to adult CKD patients without
dialysis (both p<0.05; ﬁg. 3.10). Notably, a negative correlation between the cholesterol
acceptor capacity of serum and HDL, and the cholesterol eux capacity of HMDM could
be found (ﬁg. 3.11, B, C). It is tempting to speculate that, when the cholesterol acceptor
capacities of serum and HDL decrease, the cells try to compensate by enhancing the
rate of cholesterol eux.
In conclusion the data of this study suggests that the diminished capacity of serum to act
as an acceptor for cellular cholesterol in HD patients, may be due to the lower quantity
of HDL and apoA-I. Together with alterations in HDL composition reported to occur
in CKD this may enhance the progression of atherosclerosis. Our results also point to
the possibility that human monocyte-derived macrophages may adapt to the diminished
cholesterol acceptor capacity of uremic serum by enhancing the rate of cholesterol eux.
Finally, our ﬁndings suggest that treatment modalities, which aim to raise the reduced
cholesterol acceptor capacity of serum in hemodialysis patients by increasing plasma
apoA-I levels or by applying apoA-I mimetic peptides may be promising approaches to
slow down the rapid progression of atherosclerosis in this group of patients.
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5 Abstract
Atherosclerosis, a chronic, progressive disease is highly prevalent in CKD. One of the
primary events of atherosclerosis is the accumulation of modiﬁed LDL in the macrophages
of the subendothelial matrix which leads to foam cell formation, subsequent formation of
fatty streaks and eventually enhanced CV morbidity and mortality. The converse event,
cellular cholesterol eux, is part of a process referred to as reverse cholesterol transport,
in which excess cholesterol is removed from peripheral cells and transported back to
the liver for excretion. To prevent foam cell formation and atherosclerosis development
eﬃcient cholesterol eux is crucial, but this process may be impaired in CKD due to
alterations in HDL composition and function.
This study aimed to investigate the cholesterol acceptor capacity of serum and HDL
obtained from adult and pediatric CKD patients, dialysis patients and healthy, matched
controls, as well as the cholesterol eux capacity of HMDM isolated from the study
participants.
It could be shown that, while in adult CKD patients stage 3-5 the cholesterol acceptor
capacity of serum was increased signiﬁcantly, in dialysis patients the opposite, a signif-
icant decrease occured. In HMDM obtained from adult patients with CKD stage 3-5
cholesterol eux capacity to serum and HDL was unaltered, while in dialysis patients
both was increased signiﬁcantly compared to controls.
The cholesterol acceptor capacity of serum from adult and dialysis patients correlated
positively with serum apoA-I levels, which was even more pronounced in the group
of dialysis patients. Moreover, the cholesterol accceptor capacity of serum measured
in pediatric CKD patients was, despite low HDL levels, not diminished compared to
controls, which might be due to their unaltered serum apoA-I concentration. These
data indicate that the serum apoA-I concentration is an important predictor of serum
cholesterol eux capacity.
The cholesterol acceptor capacity of HDL isolated from all adult subjects was shown
to signiﬁcantly decrease with age. Interestingly, the cholesterol acceptor capacity of
serum as well as of HDL both correlate negatively with the cholesterol eux capacity of
HMDM.
In conclusion, our data suggest that the diminished cholesterol acceptor capacity of
serum on HD patients may be due to reduced HDL and apoA-I conentrations. Together
with the alterations in HDL composition in CKD this may enhance the progression
of atherosclerosis. Furthermore, human monocyte-derived macrophages may adapt to
the diminished cholesterol acceptor capacity of uremic serum by enhancing the rate of
cholesterol eux.
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6 Zusammenfassung
Atherosklerose ist eine chronische, progressive Krankheit, die insbesondere bei Patienten
mit chronischem Nierenversagen häuﬁg auftritt. Am Beginn dieser Erkrankung steht die
Anreicherung von modiﬁzertem LDL in Makrophagen der subendothelialen Matrix was
in weiterer Folge zur Bildung von Schaumzellen, 'fatty streaks' und dann fortgeschritte-
nen atherosklerotischen Läsionen und schließlich zu erhöhter kardiovaskulärer Morbidität
und Mortalität führt. Der entgegengesetzte Prozess, der zelluläre Cholesteroleux, ist
Teil eines als Reverser Cholesteroltransport bezeichneten Stoﬀwechselweges. Dabei wird
überschüssiges Cholesterol von Zellen der Peripherie zur Leber transportiert und über
diese ausgeschieden. Um die Bildung von Schaumzellen zu verhindern ist ein eﬃzienter
Cholesteroleux essentiell. Dieser Prozess könnte jedoch wegen struktureller und funk-
tioneller Veränderungen des HDL bei chronischer Nierenkrankheit beeinträchtigt sein.
Ziel dieser Studie war es, die Kapazität von urämischem Serum und HDL zur Aufnahme
von zellulärem Cholesterol bei pediatrischen und erwachsenen Patienten mit chronischem
Nierenversagen und bei chronischen Hämodialyse-Patienten zu untersuchen. Darüber
hinaus wurde auch die Cholesteroleuxkapazität von aus dem Blut der Studienteilnehmer
isolierten HMDM studiert und mit gematchten Kontrollen verglichen.
Es konnte gezeigt werden, dass bei erwachsenen Patienten mit Nierenversagen Stadium
3-5 die Cholesterol-Akzeptor-Kapazität von Serum signiﬁkant erhöht war. Bei Dialysep-
atienten zeigte sich hingegen eine signiﬁkante Erniedrigung. Die Cholesteroleuxkapaz-
ität von HMDM zu Serum und HDL war bei erwachsenen Patienten mit Nierenversagen
Stadium 3-5 unverändert, während bei Dialysepatienten beide im Vergleich zu Kontrollen
signiﬁkant erhöht waren.
Darüber hinaus zeigte sich eine positive Korrelation zwischen der Cholesterolakzeptorka-
pazität von Serum und der Serum ApoA-I Konzentration sowohl bei erwachsenen Pa-
tienten mit Nierenversagen Stadium 3-5, als auch bei Dialysepatienten, wobei diese
Korrelation bei Dialysepatienten stärker ausgeprägt war. Bei pädiatrischen Patienten
mit CKD war die Cholesterolakzeptorkapazität von Serum trotz niedrigem HDL nicht
vermindert, was möglicherweise durch eine unveränderte Konzentration von ApoA-I im
Serum zu erklären ist. Diese Daten zeigen, dass die Konzentration von ApoA-I einen
wichtigen Prädiktor der Cholesterolakzeptorkapazität des Serums darstellt.
Bei den erwachsenen Studienteilnehmern nahm die Cholesterolakzeptorkapazität von
HDL mit zunehmendem Alter signiﬁkant ab. Interessanterweise korrelierten sowohl die
Cholesterolakzeptorkapazität von Serum als auch von HDL negativ mit der Cholesterol-
euxkapazität von HMDM.
Zusammenfassend zeigen unsere Ergebnisse eine verminderte Cholesterolakzeptorkapaz-
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ität von Serum bei Hämodialysepatienten, welche auf eine erniedrigte Konzentration von
ApoA-I und HDL zurückzuführen ist. Zusammen mit Veränderungen in der Struktur von
HDL könnte dies das Fortschreiten der Atherosklerose bei Dialysepatienten verstärken.
Darüber hinaus weisen unsere Daten darauf hin, dass HMDM sich an die verminderte
Cholesterolakzeptorkapazität von urämischem Serum anpassen, indem sie die zelluläre
Cholesteroleuxrate steigern.
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Addendum
pediatric adult dialysis
controls patients controls patients controls patients
N 12 12 17 17 14 14
Serum lipids
Cholesterol (mg/dl) 157.0±24.0 174.0±45.6 171.8±29.3 186.7±45.7 188.0±38.0 169.7±51.7
Triglycerides (mg/dl) 64.2±26.9 186.2±100.8*** 83.3±49.4 112.4±46.7 92.4±55.5 126.2±69.1
HDL (mg/dl) 48.5±9.9 32.2±13.2** 49.5±15.9 42.0±12.9 53.2±14.1 36.8±9.3**
LDL (mg/dl) 95.7±21.9 104.6±43.4 105.6±31.9 122.3±41.2 116.3±32.8 107.7±47.6
Free Cholesterol (mg/dl) 43.8±7.8 57.8±14.2** 50.2±8.2 55.7±13.3 54.4±11.2 53.4±18.1
Phospholipids (mg/dl) 179.7±21.2 207.1±44.3 216.1±26.9 210.9±40.1 299.6±35.9 213.1±65.2
Free fatty acids (mmol/l) 0.09±0.4 0.8±0.4 0.5±0.2 0.5±0.3 0.4±0.1 1.1±0.8**
Serum apoproteins
Apo-A1 (mg/dl) 126.6±13.5 121.9±32.6 155.4±27.9 145.1±32.0 166.6±29.8 132.4±27.0**
Apo-A2 (mg/dl) 29.5±2.6 30.8±13.2 35.5±4.9 34.2±7.8 41.4±7.3 31.0±5.8***
Apo-B (mg/dl) 70.3±12.0 95.8±30.5* 71.3±22.5 88.0±26.4 76.6±27.1 68.1±18.4
Apo-C2 (mg/dl) 3.1±1.5 5.8±3.1* 2.9±1.5 3.8±1.6 3.2±1.5 4.5±2.9
Apo-C3 (mg/dl) 5.7±1.6 8.2±3.6* 7.6±2.5 11.2±7.1 11.1±4.4 17.7±11.0
Apo-C2/Apo-C3 0.5±0.1 0.9±0.8 0.4±0.2 0.4±0.2 0.3±0.1 0.3±0.1
Apo-E (mg/dl) 8.3±1.9 11.1±3.5* 7.9±1.6 8.9±1.9 8.9±2.8 14.1±14.1
Lp(a) (mg/dl) 17.7±18.4 13.8±16.8 10.2±9.5 29.4±31.3* 13.8±12.5 19.5±22.3
HDL composition (%)
Cholesterol ester 14.99±5.14 11.77±3.85 14.31±3.61 13.42±3.62 15.70±4.20 13.51±2.78
Triglycerides 2.83±1.31 4.73±2.00* 4.01±1.48 4.34±1.61 3.58±1.44 3.52±1.74
Free Cholesterol 4.77±2.15 3.74±2.00 5.00±1.47 3.99±2.03 4.45±0.81 4.27±1.19
Phospholipids 28.06±5.15 26.55±5.18 34.19±8.28 30.70±5.57 31.80±3.58 31.69±4.79
Protein 49.34±9.23 53.22±7.85 42.48±12.88 47.56±11.02 44.45±5.57 47.01±8.43
Tab. 7: Clinical characteristics
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Fig. 6.1: Information for control subjects
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Fig. 6.2: Information and informed consent form for control subjects
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